Choice ✔ investment
Login

Choose stocks
✔

Create and
share portfolios

Study reporting
public companies

AGIO - Company Financial Ratios

Agios Pharmaceuticals Inc.

Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of hematologic malignancies, solid tumors, and rare genetic diseases. The company offers TIBSOVO (ivosidenib), an oral targeted inhibitor for treating adult patients with relapsed or refractory acute myeloid leukemia (R/R AML), as well as to treat patients with newly diagnosed AML; and IDHIFA, an oral targeted inhibitor for patients with R/R AML and an isocitrate dehydrogenase 2 mutation. It is also developing TIBSOVO, which has completed Phase II clinical trials to treat IC eligible frontline AML; that is in Phase III clinical trials for treating IC ineligible frontline AML; and that is in Phase III clinical trials for the treatment of cholangiocarcinoma, as well as in early stage clinical development to treat glioma and solid tumors. In addition, the company is developing IDHIFA, which has completed Phase II clinical st

United States    http://www.agios.com
Healthcare Biotechnology NASDAQ | Nasdaq Global Select

2.295 49.38

period
2021 48.04 3 321.68 - 72.03 0.00 0.00 6.60 0.000 0.00 0.75 24.69 - 24.36 - 35.52
2019 52.05 3 123.00 - 7.59 0.01 4.88 0.000 0.00 0.39 52.17 - 46.19 - 64.24
2018 51.63 2 965.00 - 8.57 0.01 4.31 0.000 0.00 0.25 214.82 - 40.31 - 50.33
2017 80.61 3 755.00 - 11.93 0.02 10.00 0.000 0.00 0.64 87.31 - 51.22 - 83.80
2016 40.51 1 585.00 28.65 - 7.99 0.01 4.42 0.000 0.00 0.73 22.68 - 32.06 - 55.35
2015 42.22 1 580.00 - 13.42 0.01 4.58 0.000 0.00 0.22 26.73 - 28.03 - 34.11